Thymosin Alpha-1 (TA1) vs BPC-157
Independent, side-by-side comparison of Thymosin Alpha-1 (TA1) and BPC-157: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.
Live price snapshot
Thymosin Alpha-1 (TA1)
BPC-157
Thymosin Alpha-1 (TA1)
Thymosin alpha-1 (Tα1) is a 28-amino-acid N-acetylated peptide (N-Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) isolated and characterized by Allan…
Live lowest price: $39.99 across 3 vendors
Full Thymosin Alpha-1 (TA1) profileBPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Live lowest price: $29.00 across 15 vendors
Full BPC-157 profileSide-by-side comparison
| Attribute | Thymosin Alpha-1 (TA1) | BPC-157 |
|---|---|---|
| Category | Immune & Inflammation | Injury, Repair & Recovery |
| Research Stage | Approved (International) | Preclinical |
| Mechanism of Action | Thymosin alpha-1 does not act through a single canonical receptor in the way many peptides do. Its mechanism is pleiotropic, involving pattern-recognition receptors, modulation of immune cell maturation and function, and shifts in cytokine signaling patterns.… | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… |
| Half-Life | ~2 hours | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. |
| Typical Dose Range | 1,600 mcg (1.6 mg) per injection (standard clinical dose) | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies |
| Dosing Frequency | Twice weekly (subcutaneous) - the approved Zadaxin schedule; alternatively 900 mcg daily for intensive short-term courses | Twice daily (AM and PM) for optimal serum levels; once daily acceptable |
| Administration | Subcutaneous | Subcutaneous, Oral, Intraperitoneal, Intravenous |
| Side Effects | Tα1 has one of the most benign side-effect profiles in the peptide space, supported by 45+ years of clinical experience in approved indications. Most users experience no acute side effects beyond mild injection site discomfort. Common (5-15% of users): -… | Generally well-tolerated. Mild nausea or GI discomfort during initial use. Temporary increase in pain/inflammation at injury site (healing response). Rare: drowsiness, dizziness, mild headache. Very rare: transient changes in blood pressure. |
| Molecular Weight | 3108 Da | 1419.5 g/mol (average); molecular formula C62H98N16O22 |
| Common Vial Sizes | 5mg, 10mg | 5mg, 10mg |
Price History
3 data points- OF
- VANDL Labs
- Ion Peptide
Price History
7 data points- OF
- BM
- Unknown
- VANDL Labs
- Unknown
- LB
- Ion Peptide
Thymosin Alpha-1 (TA1) — potential benefits
- Immune enhancement
- Antiviral defense
- Cancer adjuvant therapy
- Autoimmune modulation
- Vaccine potentiation
BPC-157 — potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Frequently asked
What's the difference between Thymosin Alpha-1 (TA1) and BPC-157?
Thymosin Alpha-1 (TA1) is a immune & inflammation that thymosin alpha-1 does not act through a single canonical receptor in the way many peptides do. its mechanism is pleiotropic, involving pattern-recognition receptors, modulation of…. BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. The two differ in mechanism, half-life (~2 hours vs Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.), and typical dose range.
Which has the longer half-life, Thymosin Alpha-1 (TA1) or BPC-157?
Thymosin Alpha-1 (TA1) has a half-life of ~2 hours. BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Thymosin Alpha-1 (TA1) or BPC-157?
Current lowest live price on BodyHackGuide: Thymosin Alpha-1 (TA1) from $39.99, BPC-157 from $29.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.
Can you stack Thymosin Alpha-1 (TA1) and BPC-157?
Stacking depends on mechanism overlap, safety profile, and goals. Thymosin Alpha-1 (TA1) and BPC-157 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Live listings from the vendors we track, refreshed continuously.
Before you buy Thymosin Alpha-1 (TA1) or BPC-157
Check the vendor trust score. Every supplier we track is rated 0–100 on COA verification, payment transparency, shipping, reviews, and listings — methodology published, no pay-to-rank.
Related comparisons
Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.